These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 20208492)
1. Researchers unite to improve Parkinson's drug discovery. Dolgin E Nat Med; 2010 Mar; 16(3):247. PubMed ID: 20208492 [No Abstract] [Full Text] [Related]
2. 4-amino-7-chloroquinoline derivatives for treating Parkinson's disease: implications for drug discovery. Kim CH; Leblanc P; Kim KS Expert Opin Drug Discov; 2016; 11(4):337-41. PubMed ID: 26924734 [No Abstract] [Full Text] [Related]
3. Recent progress in drug discovery for Parkinson's disease. Gilligan PJ Curr Top Med Chem; 2015; 15(10):905-7. PubMed ID: 25832717 [No Abstract] [Full Text] [Related]
4. Into the valley of death: research to innovation. Hudson J; Khazragui HF Drug Discov Today; 2013 Jul; 18(13-14):610-3. PubMed ID: 23402848 [TBL] [Abstract][Full Text] [Related]
6. Second International Symposium on the Treatment of Parkinson's Disease. Mizuno Y Neurology; 1998 Aug; 51(2 Suppl 2):S1. PubMed ID: 9711972 [No Abstract] [Full Text] [Related]
7. Novel insights in pharmacogenetics of drug response in Parkinson's disease. Arbouw ME; Guchelaar HJ; Egberts TC Pharmacogenomics; 2010 Feb; 11(2):127-9. PubMed ID: 20136351 [No Abstract] [Full Text] [Related]
8. Defining a new role for the National Cancer Institute cooperative groups: more science, fewer trials. Chabner BA Oncologist; 2014 Nov; 19(11):1113-4. PubMed ID: 25326160 [TBL] [Abstract][Full Text] [Related]
9. Industry is more alarmed about reproducibility than academia. Bespalov A; Barnett AG; Begley CG Nature; 2018 Nov; 563(7733):626. PubMed ID: 30487623 [No Abstract] [Full Text] [Related]
10. Recent progress in the discovery of adenosine A(2A) receptor antagonists for the treatment of Parkinson's disease. Shah U; Hodgson R Curr Opin Drug Discov Devel; 2010 Jul; 13(4):466-80. PubMed ID: 20597030 [TBL] [Abstract][Full Text] [Related]
11. LRRK2 as a therapeutic target in Parkinson's disease. Tan EK; Schapira AH Eur J Neurol; 2011 Apr; 18(4):545-6. PubMed ID: 21199179 [No Abstract] [Full Text] [Related]
12. Drug Repurposing in Parkinson's Disease. Athauda D; Foltynie T CNS Drugs; 2018 Aug; 32(8):747-761. PubMed ID: 30066310 [TBL] [Abstract][Full Text] [Related]
13. An audience with...Francis Collins. Interviewed by Asher Mullard. Collins F Nat Rev Drug Discov; 2011 Jan; 10(1):14. PubMed ID: 21151031 [No Abstract] [Full Text] [Related]
14. Movement disorders: towards new therapies in Parkinson's disease. Antonini A Lancet Neurol; 2012 Jan; 11(1):7-8. PubMed ID: 22172611 [No Abstract] [Full Text] [Related]
16. [Treatments for Parkinson's Disease -Essential Knowledge for General Physicians - Topics: III. Recommended Usage of New Antiparkinson Drugs]. Nagai M Nihon Naika Gakkai Zasshi; 2015 Aug; 104(8):1558-64. PubMed ID: 30160420 [No Abstract] [Full Text] [Related]
17. Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems. Carlsson A J Neural Transm (Vienna); 2002 May; 109(5-6):777-87. PubMed ID: 12111467 [No Abstract] [Full Text] [Related]
18. Drug treatment of Parkinson's disease. Callaghan N Ir Med J; 1983 Aug; 76(8):364-6. PubMed ID: 6618850 [No Abstract] [Full Text] [Related]
19. [A drug holiday in the treatment of Parkinson's disease]. van Manen J Ned Tijdschr Geneeskd; 1986 May; 130(20):899-902. PubMed ID: 3724863 [No Abstract] [Full Text] [Related]
20. [Revision of the treatment strategy in Parkinson's disease]. Ned Tijdschr Geneeskd; 1986 Jul; 130(28):1291-3. PubMed ID: 3748207 [No Abstract] [Full Text] [Related] [Next] [New Search]